ClinicalTrials.gg
Status unknownNCT03819946IMPACTUpdated Jan 2, 2020

Improving Oesophageal Protection During AF Ablation

An interventional study of esophageal cooling device (Attune Medical, Chicago, IL) and Standard esophageal temperature probe in Esophageal Diseases, sponsored by St. George's Hospital, London. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by St. George's Hospital, London · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Catheter ablation is an established treatment for atrial fibrillation (AF). For those with the more longstanding form of the condition and are graded as longstanding persistent AF, catheter ablation techniques often involve an extensive ablative protocol. This often includes application of ablation energy to the posterior left atrial wall. The left atrial (LA) wall is only on average 5 millimetres away from the esophageal wall. It has been shown that ablation to the posterior LA wall can cause thermal injury to the esophageal wall. Even those that require pulmonary vein isolation only can be at risk of esophageal injury. This injury can impact on patient symptoms as well as increase the risk of an atrio-esophageal fistula being formed. Esophageal protection methods during catheter ablation for AF in current practice is very limited and investigation towards improved approaches, in the form of a randomized clinical trial is required.

The aim or purpose of this research project is to study the effect of esophageal cooling on the incidence of esophageal thermal injury (endoscopy-graded esophageal epithelial lesions and/or the presence of ablation-related gastroparesis with patient symptoms) compared to controls, after a catheter ablation procedure for the treatment of AF.

Read the detailed description

Overall design This is a randomized controlled trial with 1:1 randomization to study or control group.

Treatment/intervention plan and rationale AF patients awaiting to have a planned catheter ablation procedure as their treatment will be eligible for this study. If they participate, there is a 1:1 randomization to study or control group.

The study group will have their catheter ablation procedure with utilization of esophageal protection using the cooling tubing device (Attune Medical, Chicago IL). The cooling is controlled by the procedural doctor, with temperatures set in the range of patient safety (for example, cooling at 4 degrees). This device is already in use clinically albeit in a different clinical setting. The device is currently used an intensive care setting to provide whole body cooling. It is designed to be inserted into the esophagus. The temperature control does not allow temperatures to go into the extremes, so preserving patient safety.

The control group will have their catheter ablation procedure using standard esophageal protection methods, which is an esophageal temperature probe, to measure for any temperature changes during application of ablation energy. If measured esophageal temperatures reach beyond 38 degrees then ablation is halted in that area.

Follow up endoscopy assessment After the ablation procedure, a follow up upper GI endoscopy test will be performed to review for any ablation-related thermal injury, by a group of endoscopists who are 'blinded' to the randomization of the participant. The follow up endoscopy test will be confirmed with the participant and the timing of this follow up test is within 1 week of their catheter ablation procedure.

Clinic follow up The clinic follow up will remain exactly the same as standard care but at the first clinic (this is 12 weeks or 3 months from the ablation procedure) we will review or ask about any lingering gastro-esophageal symptoms and record this in a basic questionnaire (the GerdQ questionnaire will be used).

02

Conditions studied

  • Esophageal Diseases

Browse trials for

Keywords

  • Esophageal protection
  • Ablation-related thermal injury
  • Catheter ablation for AF
  • Persistent AF ablation
03

In context

Esophageal Diseases

92 studies on the registry are indexed under Esophageal Diseases; 21 are open to participants now.

This study's planned enrollment of 120 is above the median of 50 across 66 interventional studies indexed under Esophageal Diseases.

Browse Esophageal Diseases studies →

Lead sponsor

St. George's Hospital, London is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any AF patient planned for a catheter ablation procedure or a left atrial ablation protocol that puts them at risk of surrounding structural trauma, including oesophageal injury.

Exclusion criteria

Exclusion Criteria:

  • Patients at the age extremities will not be approached for the study. (Paediatric patients or young adults (\<aged 18) or older adults over the age of 85)
  • Patients having simple or non-left atrial ablation procedures not needing oesophageal protection.
  • Patients at high risk of oesophageal bleeding e.g. oesophageal varices.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Study Group- esophgeal cooling

    In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.

    Device: esophageal cooling device (Attune Medical, Chicago, IL)

  • Active comparator
    Control group- esophgeal temperature probe

    In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.

    Other: Standard esophageal temperature probe

Interventions

  • Deviceesophageal cooling device (Attune Medical, Chicago, IL)

    The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.

  • OtherStandard esophageal temperature probe

    If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.

06

What researchers measure

Primary outcomes

  1. • The incidence of catheter ablation related esophageal injury.

    The incidence of catheter ablation related esophageal injury will be assessed by endoscopic examination. Evidence of thermal injury or symptomatic gastroparesis will be recorded. The thermal injury scale is graded 0-6. 6 being the worst score indicating severe esophageal injury. Endoscopic evidence of gastroparesis is dictated by presence of significant food residue despite \>6 hours of fasting and must be correlated with new patient symptoms post-ablation.

    Time frame: 7 days

Secondary outcomes

  1. The incidence of esophageal symptoms after catheter ablation treatment.

    During clinic assessment follow up, the participant will fill out a reflux symptoms questionnaire. This is called the GerdQ questionnaire (GerdQ stands for: gastro-esophageal reflux disease questionnaire). This is a scoring system of range 0-18, a score of 18 being the worst symptoms outcome.

    Time frame: 3 months

  2. • The incidence of major adverse outcomes (MACCE- major adverse cardiovascular cerebrovascular events) will be assessed.

    The major adverse events recorded includes the risk of cerebrovascular accident, transient ischaemic attacks (TIA) and myocardial infarction (MI). For each condition in this MACCE category- the recorded response will either be 'yes' or 'no' or 'positive' or 'negative'.

    Time frame: 12 months

  3. Long-term success rate of the catheter ablation procedure as measured from freedom from the treated arrhythmia (atrial fibrillation/atrial tachycardias).

    During clinic follow up, Holter monitors (ambulatory ECG monitors) or implantable loop recorders will monitor for any recurrence of the treated arrhythmia. Any recurrence will be recorded to assess longterm success of the catheter ablation treatment (this is objectively measured at 12 months). The outcome response is recorded as either 'yes' or 'no'.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • St.George's Hospital
    London, SW170QT, United Kingdom
    Recruiting
    • Mark M Gallagher, MD · Contactmark_m_gallagher@hotmail.com · +442087253701
    • Manav Sohal, PhD · Sub investigator
    • Abhay Bajpai, MD · Sub investigator
    • Zia Zuberi, PhD · Sub investigator
    • Anthony Li, MD · Sub investigator
    • Mark Norman, PhD · Sub investigator
    • Riyaz Kaba, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — IPD will be anonymised and stored securely in the institutional secured electronic database network. During the study, the data will be available to site sub-investigators only.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2019 (actual). Primary completion is estimated for Feb 2020, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2019
First posted
Jan 29, 2019
StartActual
Feb 1, 2019
Primary completionEst.
Feb 1, 2020
CompletionEst.
Feb 1, 2020
Last update
Jan 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03819946
Lead sponsor
St. George's Hospital, London
Collaborators
Attune Medical
Responsible party
Dr. Mark M. Gallagher (Clinical Lead for Cardiac Electrophysiology and Principal Investigator, St. George's Hospital, London) — Principal investigator
First posted
Jan 29, 2019
Start date
Feb 1, 2019
Primary completion
Feb 1, 2020 (estimated)
Completion
Feb 1, 2020 (estimated)
Last update
Jan 2, 2020

Study contacts

Sam Hollingworth, Bsc
Contact
sahollin@sgul.ac.uk
+4420287256606 ext. 6606
Mark M Gallagher, MD
principal investigator · St. George's Hospital NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion